Skip to main content

Advertisement

Log in

Interleukin-1 receptor antagonist gene polymorphism and rheumatoid arthritis

  • Original Article
  • Published:
Rheumatology International Aims and scope Submit manuscript

Abstract

The aim of this study was to evaluate the association of polymorphism in IL-1 receptor antagonist (IL-1RA) gene intron 2 with susceptibility to rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE) and their clinical features. Polymerase chain reaction of a genomic DNA was used to determine genotypes of the IL-1RA in 138 RA, 93 SLE, and 127 healthy control subjects. The frequency of IL-1RA allele 2 (IL-1RN*2) was lower in RA patients (2.5%) than in control subjects (7.1%) (odds ratio 0.34, 95% confidence interval 0.13–0.88, P=0.02). There was a significant difference in genotype and allele distribution between RA patients and controls. However, it did not differ between SLE patients and controls. In SLE and RA patients, there was no significant difference in clinical and laboratory findings concerning IL-1RA polymorphisms. In conclusion, our data suggest that IL-1RA gene polymorphism is not responsible for specific clinical characteristics in RA and SLE but that IL-1RN*2 is relevant in the susceptibility to RA, suggesting a protective role of IL-1RN*2 in the pathogenesis of RA.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1.

Similar content being viewed by others

References

  1. John S, Hajeer A, Marlow A et al (1997) Investigation of candidate disease susceptibility genes in rheumatoid arthritis: principles and strategies. J Rheumatol 24:199–201

    CAS  PubMed  Google Scholar 

  2. Witkin SS, Gerber S, Ledger WJ (2002) Influence of interleukin-1 receptor antagonist gene polymorphism on disease. Clin Inf Diseases 34:204–209

    Article  CAS  Google Scholar 

  3. Arend WP (2001) Cytokine imbalance in the pathogenesis of rheumatoid arthritis: the role of interleukin-1 receptor antagonist. Semin Arthritis Rheum 30 [Suppl 2]:1–6

    Google Scholar 

  4. Singh AK (1992) Do cytokines play a role in systemic lupus erythematosus? J R Coll Physicians Lond 26:374–376

    CAS  PubMed  Google Scholar 

  5. Tarlow JK, Blakemore AI, Lennard A et al (1993) Polymorphism in human IL-1 receptor antagonist gene intron 2 is caused by variable numbers of an 86-bp tandem repeat. Hum Genet 91:403–404

    CAS  PubMed  Google Scholar 

  6. Danis VA, Millington M, Hyland VJ et al (1995) Cytokine production by normal human monocytes: inter-subject variation and relationship to an IL-1 receptor antagonist gene polymorphism. Clin Exp Immunol 99:303–310

    CAS  PubMed  Google Scholar 

  7. Arnett FC, Edworthy SM, Kaplan SR et al (1988) The American Rheumatism Association 1987 revised criteria for classification of rheumatoid arthritis. Arthritis Rheum 31:315–324

    CAS  PubMed  Google Scholar 

  8. Tan EM, Cohen AD, Fries JF et al (1982) The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 25:1271–1277

    PubMed  Google Scholar 

  9. Bombardier C, Gladman DD, Urowitz MB, Caron D, Chang CH (1992) Derivation of the SLEDAI. A disease activity index for lupus patients. The committee on prognosis studies in SLE. Arthritis Rheum 35:630–640

    PubMed  Google Scholar 

  10. Gladman D, Ginzler E, Goldsmith C, Fortin P, Liang M, Urowitz M et al (1996) The development and initial validation of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index for systemic lupus erythematosus. Arthritis Rheum 39:363–369

    PubMed  Google Scholar 

  11. McIntyre KW, Stepan GJ, Kolinsky KD et al (1991) Inhibition of interleukin 1 binding and bioactivity in vitro and modulation of acute inflammation in vivo by IL-1 receptor antagonist and anti-IL-1 receptor monoclonal antibody. J Exp Med 173:931–939

    CAS  PubMed  Google Scholar 

  12. Tjernstrom F, Hellmer G, Nived O et al (1999) Synergetic effect between interleukin-1 receptor antagonist allele and MHC class II in determining susceptibility to systemic lupus erythematosus. Lupus 8:103–108

    CAS  PubMed  Google Scholar 

  13. McGarry F, Neilly J, Anderson N et al (2001) A polymorphism within the interleukin 1 receptor antagonist gene is associated with ankylosing spondylitis. Rheumatology 40:1359–1364

    Article  CAS  PubMed  Google Scholar 

  14. Perrier S, Coussediere C, Dbost JJ et al (1998) IL-1 receptor antagonist gene polymorphism in Sjögren’s syndrome and rheumatoid arthritis. Clin Immunol Immunopathol 87:309–313

    Google Scholar 

  15. Tarlow JK, Cork MJ, Schmidt-Egenole M et al (1997) Association between interleukin-1 receptor antagonist gene polymorphism and early and late-onset psoriasis. Br J Dermatol 136:147–148

    CAS  Google Scholar 

  16. Santila S, Savinainen K, Hume M (1998) Presence of the IL-1RA allele 2 (IL1RN*2) is associated with enhanced IL-1β production in vitro. Scand J Immunol 47:195–198

    PubMed  Google Scholar 

  17. Francis SE, Camp NJ, Burton AJ et al (2002) Interleukin 1 receptor antagonist gene polymorphism and restenosis after coronary angioplasty. Heart 86:336–340

    Article  Google Scholar 

  18. Cullup H, Dickinson AM, Jackson GH et al (2001) Donor interleukin 1 receptor antagonist genotype associated with acute graft-versus-host disease in human leukocyte antigen-matched sibling allogeneic transplants. Br J Hematol 113:807–813

    Article  CAS  Google Scholar 

Download references

Acknowledgement

This work was supported by a grant from the Korea Health 21 Research and Development Project, Ministry of Health and Welfare (01-PJ3-PG6-01GN09-003).

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Gwan Gyu Song.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Lee, Y.H., Kim, H.J., Rho, Y.H. et al. Interleukin-1 receptor antagonist gene polymorphism and rheumatoid arthritis. Rheumatol Int 24, 133–136 (2004). https://doi.org/10.1007/s00296-003-0337-9

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00296-003-0337-9

Keywords

Navigation